{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:11:26Z","timestamp":1749096686633,"version":"3.41.0"},"reference-count":84,"publisher":"Cambridge University Press (CUP)","issue":"S12","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3658,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bipolar disorder is a chronic, frequently relapsing illness with a prevalence of 1.2% to 3.4% in the general population. It is associated with high disability, higher comorbidity due to medical illnesses, and significant social and economical consequences for patients, their families, and society. The episodic nature of this disease warrants rational use of medications and proper monitoring for adverse events. Various drug classes, such as mood stabilizers, antipsychotics, benzodiazepines, and antidepressants, are used for the acute and maintenance treatment of bipolar disorder. Each group of drugs is associated with wide array of adverse events and drug interactions, which are the main hurdles in treatment outcome and compliance. Common side effects seen with several agents, particularly antipsychotics, are somnolence, weight gain, extrapyramidal symptoms, dyslipidemia, type-2 diabetes, and hyperprolactinemia. Major drug interactions are seen with drugs such as carbamazepine, due to hepatic enzyme induction. Adverse effects such as somnolence are tolerability concerns and can be managed easily; others, such as diabetes mellitus, are safety concerns. It is prudent to have precise knowledge of the individual drug's side-effect profile, pharmacokinetics, and pharmacodynamics, to plan a treatment regimen. More research is needed to understand potential rish of various drugs and to devise and incorporate monitoring protocols in the treatment regimen.<\/jats:p>","DOI":"10.1017\/s1092852900028856","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:41:25Z","timestamp":1470112885000},"page":"16-26","source":"Crossref","is-referenced-by-count":6,"title":["Safety Considerations in Pharmacotherapy of Bipolar Disorder"],"prefix":"10.1017","volume":"9","author":[{"given":"Prakash S.","family":"Masand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan S.","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"doi-asserted-by":"publisher","key":"S1092852900028856_ref038","DOI":"10.1176\/ajp.155.1.12"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref079","DOI":"10.1192\/bjp.182.3.199"},{"volume-title":"Bipolar disorder: Current Diagnosis and Treatment in Psychiatry","year":"2002","author":"Ebert","key":"S1092852900028856_ref026"},{"key":"S1092852900028856_ref007","first-page":"9","article-title":"Treatment of bipolar disorder","volume":"64","author":"Moller","year":"2003","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref025","DOI":"10.1177\/875512259501100210"},{"volume-title":"Overview of safety and tolerability of atipiprazole in acute mania","year":"2004","author":"Marcus","key":"S1092852900028856_ref062"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref027","DOI":"10.1001\/archpsyc.1979.01780080040011"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref045","DOI":"10.1016\/S0006-3223(99)00316-9"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref029","DOI":"10.4088\/JCP.v64n0906"},{"volume-title":"Manic-Depressive Illness","year":"1990","author":"Goodwin","key":"S1092852900028856_ref001"},{"author":"Weisler","journal-title":"J Ciin Psychiatry","article-title":"A multi-center, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes","key":"S1092852900028856_ref014"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref039","DOI":"10.2165\/00002018-200427030-00002"},{"volume-title":"The Global Burden of Disease","year":"1996","author":"Murray","key":"S1092852900028856_ref002"},{"key":"S1092852900028856_ref023","first-page":"1908","article-title":"Adverse affects of lithium treatment and safety routines","volume":"101","author":"Bendz","year":"2004","journal-title":"Lakaridningen"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref024","DOI":"10.2165\/00023210-200216110-00001"},{"key":"S1092852900028856_ref049","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"volume-title":"Cardiac arrest risk appears to vary little by choice of antipsychotic drug","year":"2001","author":"Hennessy","key":"S1092852900028856_ref081"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref010","DOI":"10.1002\/hup.556"},{"volume-title":"Atipiprazole for relapse prevention in bipolar disorder in 26-week trial","year":"2004","author":"Keck","key":"S1092852900028856_ref080"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref022","DOI":"10.1017\/S1092852900008166"},{"key":"S1092852900028856_ref058","first-page":"179","article-title":"Prevalence of overweight and obesity in bipolar patients","volume":"61","author":"Elmslie","year":"2000","journal-title":"J Ciin Psychiatry"},{"key":"S1092852900028856_ref041","first-page":"172","article-title":"Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy","volume":"56","author":"Biton","year":"2001","journal-title":"Neurobgy"},{"key":"S1092852900028856_ref069","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1152\/physrev.1995.75.3.473","article-title":"Pathophysiology of insulin resistance in human disease","volume":"75","author":"Reaven","year":"1995","journal-title":"Physiol Rev."},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref028","DOI":"10.1055\/s-2007-979586"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref059","DOI":"10.1586\/14737167.3.5.651"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref008","DOI":"10.1001\/archpsyc.57.9.841"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref011","DOI":"10.1001\/jama.1994.03510360044034"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref051","DOI":"10.1097\/00004850-199100610-00006"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref012","DOI":"10.4088\/JCP.v60n0203"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref053","DOI":"10.1097\/01.jcp.0000104912.75206.2b"},{"key":"S1092852900028856_ref005","first-page":"276","article-title":"Synergy of carbamazepine and valproic acid in affective illness: case report and review of literature","volume":"12","author":"Ketter","year":"1992","journal-title":"J Clin Psychopharmacol"},{"volume-title":"Adjunctive zonisamide as immediate treatment of bipolar disorder outpatients","year":"2002","author":"Baldassano","key":"S1092852900028856_ref018"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref050","DOI":"10.1111\/j.1600-0447.1992.tb03264.x"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref006","DOI":"10.1034\/j.1399-5618.2000.020202.x"},{"key":"S1092852900028856_ref060","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref063","DOI":"10.1001\/archpsyc.59.1.62"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref013","DOI":"10.1016\/S0006-3223(00)00961-6"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref072","DOI":"10.1097\/00004583-200203000-00014"},{"key":"S1092852900028856_ref021","first-page":"161","article-title":"Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder","volume":"64","author":"Hirschfeld","year":"2003","journal-title":"J Ciin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref047","DOI":"10.1176\/appi.ajp.160.9.1651"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref044","DOI":"10.1097\/00004714-200212000-00010"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref075","DOI":"10.1592\/phco.23.6.735.32178"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref052","DOI":"10.1111\/j.1532-5415.1999.tb01595.x"},{"key":"S1092852900028856_ref078","first-page":"596","article-title":"American Psychiatric Association; Ametican Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"S1092852900028856_ref031","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1176\/ajp.147.4.431","article-title":"Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder","volume":"147","author":"Calabrese","year":"1990","journal-title":"Am J Psychiatry"},{"unstructured":"Tegretol\u00ae [package insert]: East Hanover, NJ: Novartis Pharmaceuticals Corp; 2001.","key":"S1092852900028856_ref037"},{"key":"S1092852900028856_ref057","first-page":"551","article-title":"Management of obesity: medical treatment options","volume":"55","author":"Carek","year":"1997","journal-title":"Am Fam Physician"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref061","DOI":"10.1176\/appi.ajp.159.7.1146"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref066","DOI":"10.1017\/S1092852900008154"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref017","DOI":"10.1016\/S0165-0327(98)00110-4"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref034","DOI":"10.1055\/s-2002-37081"},{"key":"S1092852900028856_ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(02)80147-X","volume-title":"Olanzapine-fluoxetine combination for psychotic major depression","author":"Dube","year":"2002"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref054","DOI":"10.1176\/appi.ajp.158.9.1511"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref074","DOI":"10.4088\/JCP.v65n0619"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref056","DOI":"10.1001\/jama.1996.03540230057036"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref019","DOI":"10.1097\/00004850-200405000-00001"},{"unstructured":"Macritchie K , Geddes JR , Scott J , et al. Valproate (Cochrane review). Issue 4. 2004.","key":"S1092852900028856_ref033"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref042","DOI":"10.1001\/archpsyc.57.5.481"},{"volume-title":"Insulin tesistance in olanzapine and ziprasidone treated patients: results of a double-blind, controlled 6-week trial","year":"2001","author":"Click","key":"S1092852900028856_ref073"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref067","DOI":"10.1016\/S0735-1097(02)02529-9"},{"key":"S1092852900028856_ref070","first-page":"339","article-title":"Some actions of chlorpromazine","volume":"11","author":"Ryall","year":"1956","journal-title":"Br J Pharmacol"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref071","DOI":"10.4088\/PCC.v03n0203"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref020","DOI":"10.1046\/j.1440-1614.2003.01207.x"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref064","DOI":"10.1097\/01.jcp.0000130556.01373.45"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref046","DOI":"10.1176\/appi.ajp.157.4.514"},{"volume-title":"Ziprasidone's long-term efficacy and safety in bipolar disorder","year":"2004","author":"Keck","key":"S1092852900028856_ref065"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref003","DOI":"10.1001\/archpsyc.58.9.844"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref055","DOI":"10.1001\/jama.286.10.1195"},{"unstructured":"FDA Psychopharmacological Drug Advisory Committee. Pfizer study 54-07 19, 2000.","key":"S1092852900028856_ref082"},{"author":"Ketter","journal-title":"J Ciin Psychiatry","article-title":"A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes","key":"S1092852900028856_ref015"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref036","DOI":"10.1016\/S0165-0327(99)00125-1"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref004","DOI":"10.1016\/S0006-3223(03)00420-7"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref043","DOI":"10.4088\/JCP.v64n0506"},{"key":"S1092852900028856_ref068","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1046\/j.1463-1326.2000.00001.x","article-title":"Risk factots for vascular disease in patients with diabetes","volume":"2","author":"Btown","year":"2000","journal-title":"Diabetes Obes Metab"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref083","DOI":"10.1016\/0002-9149(93)90035-B"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref040","DOI":"10.2165\/00003495-200363190-00009"},{"key":"S1092852900028856_ref048","first-page":"16","article-title":"Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence","volume":"65","author":"Kane","year":"2004","journal-title":"J Ciin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref076","DOI":"10.1592\/phco.22.11.841.33629"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref077","DOI":"10.1176\/appi.ajp.160.2.290"},{"volume-title":"Data on file","year":"2003","key":"S1092852900028856_ref016"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref084","DOI":"10.1017\/S1092852900000973"},{"unstructured":"Depakon\u00ae [package insert]. North Chicago, Il: Abbott laboratories; 2000.","key":"S1092852900028856_ref032"},{"doi-asserted-by":"publisher","key":"S1092852900028856_ref030","DOI":"10.1034\/j.1399-5618.2003.00031.x"},{"key":"S1092852900028856_ref035","first-page":"943","article-title":"Oxcarbazepine treatment of bipolar disorder","volume":"64","author":"Ghaemi","year":"2003","journal-title":"J Ciin Psychiatry"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900028856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:57:21Z","timestamp":1749034641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900028856\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":84,"journal-issue":{"issue":"S12","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S1092852900028856"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900028856","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"type":"print","value":"1092-8529"},{"type":"electronic","value":"2165-6509"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}